0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Mother With Amyotrophic Lateral Sclerosis and Daughter With Creutzfeldt-Jakob Disease FREE

Bradford B. Worrall, MD; Lewis P. Rowland, MD; Maura Del Bene, RN; Dora Leung, MD; Steven S.-M. Chin, MD, PhD
[+] Author Affiliations

From the Departments of Neurology (Drs Worrall, Rowland, and Leung and Ms Del Bene) and Pathology (Dr Chin), Columbia University College of Physicians & Surgeons, New York, NY. Dr Worrall is now with the Department of Neurology, University of Virginia Health System, Charlottesville.


Arch Neurol. 1999;56(12):1502-1504. doi:10.1001/archneur.56.12.1502.
Text Size: A A A
Published online

ABSTRACT

Objective  To describe a mother who had autopsy-proved amyotrophic lateral sclerosis and her daughter who had clinically diagnosed Creutzfeldt-Jakob disease.

Design  Case reports with molecular genetic analyses.

Setting  A tertiary care center.

Patients  The mother had progressive upper and lower motor neuron symptoms and signs starting at the age of 54 years. Electrophysiological testing supported the diagnosis of amyotrophic lateral sclerosis. Autopsy results confirmed the diagnosis. Her daughter had received injections of human growth hormone prepared from pooled human pituitary glands as a child. At the age of 31 years, she experienced the onset of gait ataxia and dysarthria. Cerebrospinal fluid showed the 14-3-3 protein. Cognitive difficulties ensued. She progressed to a nearly akinetic and mute state. She had overt visible fasciculations and muscle atrophy in the legs.

Main Outcome Measures and Results  Neither patient carried a mutation in the prion protein gene. Both were homozygous for methionine at the polymorphic codon 129. Neither patient carried a deletion of the 5 exons of the superoxide dismutase 1 gene.

Conclusions  It is uncertain whether the 2 cases occurred in the same family by chance or whether the patients shared genetic risk factors for the 2 diseases. The possibility that homozygosity at codon 129 is a risk factor for amyotrophic lateral sclerosis is being tested in a case-control study.

THE cause of sporadic amyotrophic lateral sclerosis (ALS) is unknown. Of the cases, 5% to 10% are familial, and the superoxide dismutase 1 (SOD1) gene mutation accounts for only about 20% of these cases. It is, therefore, appropriate to remain open minded about possible causes or modes of pathogenesis. We encountered a mother with ALS and her daughter with growth hormone–induced Creutzfeldt-Jakob disease (CJD), a combination not previously reported, to our knowledge. The likelihood of this co-occurrence must be small, as statistically unlikely as conjugal cases of either ALS1 or CJD.2 Although the minicluster is probably a statistical coincidence, the 2 conditions may be related.

PATIENTS AND METHODS

PATIENT 1 (THE MOTHER)
Patient Characteristics

At the age of 54 years, in February 1995, this woman noted weakness of the right hand. In November 1995, there was weakness and wasting of muscles of the right hand and arm; fasciculation was seen in both arms. Tendon reflexes were overactive throughout, with bilateral Hoffmann signs and clonus at the right ankle but no Babinski sign. In August 1997, she was quadriplegic, barely able to make sounds or swallow, and constantly dyspneic. Fasciculations were seen in the tongue. Her neck movements were weak, and the limbs were immobile. Fasciculation was still evident in the biceps, and tendon reflexes were still overactive except for absent ankle jerks. There were no Hoffmann or Babinski signs. The results of laboratory studies showed no conduction block, monoclonal paraprotein, or antibodies to GM1 or myelin-associated glycoprotein. Examination of the cerebrospinal fluid showed no abnormality, and electromyography gave evidence of chronic denervation in 3 limbs. The patient died in August 1997, 30 months after the onset of symptoms.

Autopsy Results

The autopsy was performed by one of us (S.S.C). The number of Betz cells in the precentral gyrus was much decreased, particularly in the leg area. In the cerebral peduncle of a midbrain section, the pyramidal tract showed vacuolar change and foamy macrophages. The medulla showed neuronal loss in the hypoglossal nucleus and reactive astrogliosis. In the spinal cord, there was marked loss of large motor neurons at all levels, with only rare chromatolytic changes. Occasional Bunina bodies, spheroids, and astrogliosis were seen. The anterior and lateral corticospinal tracts showed loss of myelinated fibers with marked pallor, vacuolar changes, and foamy macrophages. The thoracic nucleus was unremarkable. The anterior nerve roots were atrophic; the posterior nerve roots were normal. No senile plaques, neurofibrillary tangles, or Lewy bodies were seen. There was some spongy change in layer II of the precentral gyrus but no frank spongiosis. The findings were typical of ALS, with no histological evidence of prion protein (PrP) disease. There was no evidence of protease-resistant PrP by Western blot analysis of a section of brain cortex and upper spinal cord using the monoclonal anti–PrP 3F4 antibody.3

PATIENT 2

The daughter of patient 1 was born in 1964. Between the ages of 8 and 12 years, she was treated for short stature with injections of human growth hormone prepared from cadaver-derived pituitary glands. Some lots of the hormone she received were tested for prion protein and were found to transmit CJD to primates.4 She was neurologically asymptomatic until August 1995. Ataxia of gait and dysarthria progressed rapidly. In November 1995, James R. Miller, MD, found good cognition, severe dysmetria in all limbs, rigidity and spasticity, hyperactive tendon jerks, and bilateral Babinski signs. He noted no myoclonus. The results of brain magnetic resonance imaging and cerebrospinal fluid examinations were normal. The cerebrospinal fluid was tested in the laboratory of Paul Brown, MD, and showed the 14-3-3 protein.5 Dementia followed, and she remains in a long-term care facility. In August 1997, she was found by one of us (B.B.W.) to be mute and unresponsive to voice, bright light, noise, and visual threat. She had no startle responses or myoclonic jerks. Spontaneous and oculocephalic eye movements were of full range. The fundi and corneal reflexes were normal. Snout reflexes were active, but no pharyngeal reflex was elicited. No fasciculation was seen in the tongue. Her limbs were immobile and spastic, with flexion contractures at the knee and ankle. There was atrophy of distal leg muscles, and fasciculations were seen in the feet, gastrocnemius muscles, and quadriceps but not in the torso or arms. Tendon reflexes were overactive throughout, with bilateral Babinski signs and left ankle clonus.

FAMILY HISTORY

There was no consanguinity. The mother had an asymptomatic son and daughter in addition to the affected daughter. There was no other neurologic or psychiatric disease in the family.

RESULTS

MOLECULAR GENETICS
Methods

Screening for a PRP gene mutation was carried out by denaturing gradient gel electrophoresis6 of DNA extracted from white blood cells, with amplification by the polymerase chain reaction of the open reading frame of the PRP gene. Confirmation of sequences was performed with an automated DNA sequencer. The entire region of the open reading frame was sequenced bidirectionally using dye-primer chemistry. Screening for the SOD1 gene mutation was performed similarly using genomic DNA prepared from the patients' blood samples using a standard technique. All 5 exons were amplified by polymerase chain reaction from genomic DNA using specific pairs of primers designed according to published sequences.7 Screening for point mutations was performed by single strand conformation polymorphism against positive and negative controls.7

Results

In both subjects, the sequence of the PRP gene was normal. In both, the polymorphic codon 129 of the PRP gene was homozygous for methionine. In addition, we found no deletion or abnormal patterns of the 5 exons of the SOD1 gene in either subject.7

PRION GENETICS AND SUSCEPTIBILITY TO PRION DISEASES

In this family, the daughter had the characteristic clinical findings of iatrogenic growth hormone–related CJD, as well as a positive 14-3-3 protein test result. She had both upper and lower motor neuron signs, including amyotrophy. However, the diagnosis has not been proved by pathological features, documentation of PrP deposition, or transmission.8 Autopsy examination of the mother confirmed the clinical diagnosis and showed typical ALS pathological features with no spongiform change. Gene sequencing failed to reveal a mutation in the PRP gene in either, and the mother met none of the criteria for prion disease. Both were homozygous for methionine at codon 129 of the PRP gene.

The polymorphism at codon 129 of the PRP gene modifies the risk of sporadic and iatrogenic CJD and alters the phenotype and course of certain familial prion diseases. Among normal individuals in several countries, about half of the people are homozygous for either methionine or valine.9,10 In contrast, in people with iatrogenic CJD induced by cerebral transmission (electrodes and dural grafts), 93% are homozygous at codon 129, as are 91% of those who received growth hormone prepared from human pituitary glands.1113 The frequency of homozygosity at codon 129 is also much higher in persons with sporadic CJD than in the general population.1416

Sporadic prion syndromes may also differ clinically and pathologically as a result of the polymorphisms at codon 129.17 Familial CJD and fatal familial insomnia result from a mutation at codon 178.18 In these families, codon 129 of the PRP gene encodes valine in those with CJD and methionine in those with fatal familial insomnia. The codon 129 polymorphism on the nonmutant PRP gene also influences the rate of disease progression.19 This polymorphism may influence the age at onset and duration of other familial prion diseases20 and may impair cognitive performance in people without prion disease.21

Since the mother and daughter described herein were homozygous for methionine at codon 129, they were presumably at higher risk for prion disease than are heterozygous people. However, there was no clinical, DNA, or histopathological evidence that the mother had a prion disease. There was no mutation of the PRP gene sequenced from the DNA of blood leukocytes of the mother or daughter. The cerebrospinal fluid test5 was not applied to the mother, and a brain biopsy has not been proposed for the daughter.

COMMENT

These cases remind us that these 2 neurodegenerative conditions occasionally share clinical features. In 1 series,22 10% of patients with CJD showed amyotrophy. In the present study, the daughter had fasciculations and wasting; to our knowledge, she is the first person described with iatrogenic CJD and amyotrophy. The concurrence of the 2 diseases in mother and daughter could be merely a horrible coincidence, the daughter having inherited the "prion susceptibility" polymorphic genotype from her parents and then being challenged with an inoculum of prions from growth hormone. This would have no implications whatsoever about the pathogenesis of ALS in her mother or anyone else.

The issues raised by this family suggest a need for further study. The possibility that homozygosity at codon 129 is a risk factor for ALS is being tested in a case-control study. We address the significance of amyotrophy in prion disease in a separate review.

ARTICLE INFORMATION

Accepted for publication January 19, 1999.

We thank James Mastrianni, MD, PhD, Department of Neurology, University of Chicago School of Medicine, Chicago, Ill, for carrying out the prion protein gene analyses and for advice and criticism in preparing the manuscript; Serge Przedborski, MD, PhD, Department of Neurology, Columbia-Presbyterian Medical Center, New York, NY, for screening for the superoxide dismutase 1 gene mutation; and Arthur P. Hays, MD, Department of Pathology, Columbia-Presbyterian Medical Center, for giving advice and help throughout the study.

Reprints: Bradford B. Worrall, MD, Department of Neurology–394, University of Virginia Health System, Charlottesville, VA 22908 (e-mail: bbw9r@virginia.edu).

REFERENCES

Camu  WCadilhac  JBilliard  M Conjugal amyotrophic lateral sclerosis: report of two couples from southern France. Neurology. 1994;44547- 548
Link to Article
Brown  PCervenakova  LMcShane  L  et al.  Creutzfeldt-Jakob disease in a husband and wife. Neurology. 1998;50684- 688
Link to Article
Kascsak  RJRubenstein  RMerz  PA  et al.  Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol. 1987;613688- 3693
Brown  PGajdusek  DCGibbs  CJ  JrAsher  DM Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med. 1985;313728- 731
Link to Article
Hsich  GKenney  KGibbs  CJ  JrLee  KHarrington  MG The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongioform encephalopathies. N Engl J Med. 1996;335924- 930
Link to Article
Mastrianni  JAIannicola  CMyers  RMDeArmond  SPrusiner  SB Mutation of the prion protein gene at codon 208 in familial Creutzfeldt-Jakob disease. Neurology. 1996;471305- 1312
Link to Article
Rosen  DRSiddique  TPatterson  D  et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;36259- 62
Link to Article
De Vilemeur  TBDeslys  JPPradel  A  et al.  Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology. 1996;47690- 695
Link to Article
Laplanche  JLDelasnerie  NBrandel  JP  et al.  Molecular genetics of prion diseases in France. Neurology. 1994;442347- 2351
Link to Article
Gabizon  RRosemann  HMeiner  Z  et al.  Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease. Am J Hum Genet. 1993;53828- 835
Brown  PPreece  MAWill  RG Friendly fire in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet. 1992;34024- 27
Link to Article
Brown  PCervenakova  LGoldfarb  L  et al.  Iatrogenic CJD: example of the interplay between ancient genes and modern medicine. Neurology. 1994;44291- 293
Link to Article
Collinge  JPalmer  MSDryden  AJ Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet. 1991;3371441- 1442
Link to Article
Palmer  MSDryden  AHughes  J TrevorCollinge  J Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352340- 342
Link to Article
Salvatore  MGenuardi  MPetraroli  R  et al.  Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease. Hum Genet. 1994;94375- 379
Link to Article
Petraroli  RPocchiari  M Codon 129 polymorphism of PRNP in healthy caucasians and Creutzfeldt-Jakob disease patients. Am J Hum Genet. 1996;58888- 889
Parchi  PCastellani  RCapellari  S  et al.  Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39767- 778
Link to Article
Goldfarb  LBrown  P The transmissible spongiform encephalopathies. Annu Rev Med. 1995;4657- 65
Link to Article
Gambetti  PL A tale of two diseases with the same genetic mutation. Curr Top Microbiol Immunol. 1996;20719- 25
Baker  HFPoulter  MCrow  TJ  et al.  Amino acid polymorphism in human prion protein and age at death in inherited prion disease [letter]. Lancet. 1991;3371286
Link to Article
Berr  CRichard  FDufouil  CAmant  CAlperovitch  AAmouyel  P Polymorphisms of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology. 1998;51734- 737
Link to Article
Kovanen  J Clinical characteristics of familial and sporadic Creutzfeldt-Jakob disease in Finland. Acta Neurol Scand. 1993;87469- 474
Link to Article

Figures

Tables

References

Camu  WCadilhac  JBilliard  M Conjugal amyotrophic lateral sclerosis: report of two couples from southern France. Neurology. 1994;44547- 548
Link to Article
Brown  PCervenakova  LMcShane  L  et al.  Creutzfeldt-Jakob disease in a husband and wife. Neurology. 1998;50684- 688
Link to Article
Kascsak  RJRubenstein  RMerz  PA  et al.  Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol. 1987;613688- 3693
Brown  PGajdusek  DCGibbs  CJ  JrAsher  DM Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med. 1985;313728- 731
Link to Article
Hsich  GKenney  KGibbs  CJ  JrLee  KHarrington  MG The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongioform encephalopathies. N Engl J Med. 1996;335924- 930
Link to Article
Mastrianni  JAIannicola  CMyers  RMDeArmond  SPrusiner  SB Mutation of the prion protein gene at codon 208 in familial Creutzfeldt-Jakob disease. Neurology. 1996;471305- 1312
Link to Article
Rosen  DRSiddique  TPatterson  D  et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;36259- 62
Link to Article
De Vilemeur  TBDeslys  JPPradel  A  et al.  Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology. 1996;47690- 695
Link to Article
Laplanche  JLDelasnerie  NBrandel  JP  et al.  Molecular genetics of prion diseases in France. Neurology. 1994;442347- 2351
Link to Article
Gabizon  RRosemann  HMeiner  Z  et al.  Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease. Am J Hum Genet. 1993;53828- 835
Brown  PPreece  MAWill  RG Friendly fire in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet. 1992;34024- 27
Link to Article
Brown  PCervenakova  LGoldfarb  L  et al.  Iatrogenic CJD: example of the interplay between ancient genes and modern medicine. Neurology. 1994;44291- 293
Link to Article
Collinge  JPalmer  MSDryden  AJ Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet. 1991;3371441- 1442
Link to Article
Palmer  MSDryden  AHughes  J TrevorCollinge  J Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352340- 342
Link to Article
Salvatore  MGenuardi  MPetraroli  R  et al.  Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease. Hum Genet. 1994;94375- 379
Link to Article
Petraroli  RPocchiari  M Codon 129 polymorphism of PRNP in healthy caucasians and Creutzfeldt-Jakob disease patients. Am J Hum Genet. 1996;58888- 889
Parchi  PCastellani  RCapellari  S  et al.  Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39767- 778
Link to Article
Goldfarb  LBrown  P The transmissible spongiform encephalopathies. Annu Rev Med. 1995;4657- 65
Link to Article
Gambetti  PL A tale of two diseases with the same genetic mutation. Curr Top Microbiol Immunol. 1996;20719- 25
Baker  HFPoulter  MCrow  TJ  et al.  Amino acid polymorphism in human prion protein and age at death in inherited prion disease [letter]. Lancet. 1991;3371286
Link to Article
Berr  CRichard  FDufouil  CAmant  CAlperovitch  AAmouyel  P Polymorphisms of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology. 1998;51734- 737
Link to Article
Kovanen  J Clinical characteristics of familial and sporadic Creutzfeldt-Jakob disease in Finland. Acta Neurol Scand. 1993;87469- 474
Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles